Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03631407 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT03631407 is a Phase 2 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 41 participants.
The verdict
NCT03631407, a Phase 2 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
This trial will evaluate the safety and efficacy of vicriviroc (MK-7690) at 2 dose levels in combination with pembrolizumab (MK-3475) in participants with advanced/metastatic microsatellite stable (MSS) colorectal cancer (CRC).
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Vicriviroc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-09-24 |
| Est. Completion | 2021-06-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03631407
The ClinicalTrials.gov registry entry for NCT03631407 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03631407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03631407 about?
NCT03631407 is a clinical study titled "Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)". This trial will evaluate the safety and efficacy of vicriviroc (MK-7690) at 2 dose levels in combination with pembrolizumab (MK-3475) in participants with advanced/metastatic microsatellite stable (MSS) colorectal cancer (CRC).
What is the current status of trial NCT03631407?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2018-09-24. Estimated completion is 2021-06-08.
What interventions are being tested in trial NCT03631407?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Vicriviroc (DRUG).
Who is sponsoring clinical trial NCT03631407?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.